Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (211-220 of 302) with videos related to

Pageof 31
Sort By:
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Blood|September 2, 2020
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOPCiara L Freeman, Kerry J Savage, Diego R Villa, et al.
Leukemia & Lymphoma|October 6, 2015
Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression statusSamantha Kendrick, Katalin Tus, George Wright, et al.
Blood|May 5, 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie, Joseph M Connors, Gordon L Phillips, et al.
Blood|February 25, 2018
High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphologyDavid W Scott, Rebecca L King, Annette M Staiger, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Blood|July 12, 2019
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphomaAnja Mottok, Stacy S Hung, Elizabeth A Chavez, et al.
Blood Advances|August 26, 2021
Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approachPhoebe T M Cheng, Diego Villa, R Petter Tonseth, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|October 23, 2019
Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral HeterogeneityMichael D Nissen, Manabu Kusakabe, Xuehai Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
Pageof 31

Showing results (211-220 of 302) with videos related to

Sort By:
Pageof 31
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Blood|September 2, 2020
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOPCiara L Freeman, Kerry J Savage, Diego R Villa, et al.
Leukemia & Lymphoma|October 6, 2015
Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression statusSamantha Kendrick, Katalin Tus, George Wright, et al.
Blood|May 5, 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie, Joseph M Connors, Gordon L Phillips, et al.
Blood|February 25, 2018
High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphologyDavid W Scott, Rebecca L King, Annette M Staiger, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Blood|July 12, 2019
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphomaAnja Mottok, Stacy S Hung, Elizabeth A Chavez, et al.
Blood Advances|August 26, 2021
Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approachPhoebe T M Cheng, Diego Villa, R Petter Tonseth, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|October 23, 2019
Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral HeterogeneityMichael D Nissen, Manabu Kusakabe, Xuehai Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
Pageof 31